Curis Stock - Analyst focus and biotech sector review
19.06.2026 - 17:16:17 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 17:14 CET. Details in the imprint.
Curis (US2312691006) is a clinical-stage oncology company listed on Nasdaq with no new market-moving corporate announcements published today, according to exchange and company disclosures checked this Friday. With the news flow muted, the focus turns to how analysts currently rate the stock and how it sits within the volatile small-cap biotech sector.
Curis stock - news, data and background
All current disclosures, background pieces and price data on Curis stock are bundled on the ad hoc news topic page and on the company's Investor Relations site.
How analysts view Curis
Curis has a micro-cap profile and limited analyst coverage compared with larger biotech peers. According to data collated by MarketWatch and Nasdaq, only a small handful of brokerage firms currently publish regular research on the stock.
Consensus figures show that recent target prices discussed in the market cluster well above the current single-digit share price, reflecting the binary nature of clinical-stage biotech valuation rather than near-term cash flow visibility. Rating stances range from speculative Buy calls to more cautious Hold recommendations, underlining substantial uncertainty around trial outcomes.
Friday review and sector context
On this Friday, there are no fresh Curis-specific press releases, SEC filings or Reuters/Bloomberg headlines altering the fundamental picture. The company's last material announcement dates back several weeks and related to development progress and financing, not to a finalized commercial launch.
Sector-wide, small-cap biotech has traded in a choppy pattern in recent months, with investors alternating between risk-on phases and flights to safety in larger, cash-generative pharmaceutical names. Curis shares tend to move with this broader sentiment, reacting more strongly on days when trial readouts or financing news hit the tape across the industry.
How Curis seeks to make money
Curis focuses on targeted cancer therapies, including the oral IRAK4 inhibitor emavusertib (also known as CA-4948), which is studied in hematologic malignancies and certain solid tumors. As a clinical-stage biotech, Curis currently generates only modest revenue, mainly from collaboration and licensing agreements, while funding operations through equity, partnerships and other financing tools.
Where the stock trades today
The shares of Curis (US2312691006) trade on Nasdaq under the ticker CRIS at $0.53 as of 06/19/2026, 11:10 ET.
Key facts on Curis stock
- Company: Curis Inc.
- ISIN: US2312691006
- WKN: 923998
- Ticker: CRIS
- Venue: Nasdaq
- Price (as of 06/19/2026, 11:10 ET): 0.53 USD
- Market cap: 62,000,000 USD (as of 06/19/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: not included in major benchmarks such as the S&P 500 or Nasdaq-100
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
